nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—MAPK8—rheumatoid arthritis	0.27	0.592	CbGaD
Nilotinib—BLK—rheumatoid arthritis	0.186	0.408	CbGaD
Nilotinib—ABCG2—Leflunomide—rheumatoid arthritis	0.0267	0.133	CbGbCtD
Nilotinib—ABCG2—Sulfasalazine—rheumatoid arthritis	0.0165	0.0822	CbGbCtD
Nilotinib—ABCG2—Hydrocortisone—rheumatoid arthritis	0.0132	0.066	CbGbCtD
Nilotinib—ABCG2—Cyclosporine—rheumatoid arthritis	0.0125	0.0623	CbGbCtD
Nilotinib—CYP2C9—Leflunomide—rheumatoid arthritis	0.00992	0.0494	CbGbCtD
Nilotinib—ABCG2—Dexamethasone—rheumatoid arthritis	0.00823	0.041	CbGbCtD
Nilotinib—ABCB1—Methylprednisolone—rheumatoid arthritis	0.00785	0.0391	CbGbCtD
Nilotinib—CYP2C8—Hydrocortisone—rheumatoid arthritis	0.00705	0.0352	CbGbCtD
Nilotinib—CA6—submandibular gland—rheumatoid arthritis	0.00681	0.123	CbGeAlD
Nilotinib—CYP2C8—Cyclosporine—rheumatoid arthritis	0.00666	0.0332	CbGbCtD
Nilotinib—ABCG2—Methotrexate—rheumatoid arthritis	0.00661	0.033	CbGbCtD
Nilotinib—CYP3A4—Ergocalciferol—rheumatoid arthritis	0.00638	0.0318	CbGbCtD
Nilotinib—CYP2B6—Dexamethasone—rheumatoid arthritis	0.00579	0.0289	CbGbCtD
Nilotinib—ABCB1—Betamethasone—rheumatoid arthritis	0.0051	0.0254	CbGbCtD
Nilotinib—ABCB1—Prednisolone—rheumatoid arthritis	0.00503	0.0251	CbGbCtD
Nilotinib—ABCB1—Hydrocortisone—rheumatoid arthritis	0.00477	0.0238	CbGbCtD
Nilotinib—ABCB1—Prednisone—rheumatoid arthritis	0.00475	0.0237	CbGbCtD
Nilotinib—CYP3A4—Methylprednisolone—rheumatoid arthritis	0.0047	0.0234	CbGbCtD
Nilotinib—CYP2C9—Cyclosporine—rheumatoid arthritis	0.00464	0.0232	CbGbCtD
Nilotinib—ABCB1—Cyclosporine—rheumatoid arthritis	0.00451	0.0225	CbGbCtD
Nilotinib—CYP2C8—Dexamethasone—rheumatoid arthritis	0.00438	0.0219	CbGbCtD
Nilotinib—CYP2D6—Cyclosporine—rheumatoid arthritis	0.00425	0.0212	CbGbCtD
Nilotinib—CYP3A4—Triamcinolone—rheumatoid arthritis	0.00356	0.0178	CbGbCtD
Nilotinib—MAPK8—cartilage tissue—rheumatoid arthritis	0.00318	0.0574	CbGeAlD
Nilotinib—CYP2C9—Dexamethasone—rheumatoid arthritis	0.00306	0.0152	CbGbCtD
Nilotinib—CYP3A4—Betamethasone—rheumatoid arthritis	0.00306	0.0152	CbGbCtD
Nilotinib—CYP3A4—Prednisolone—rheumatoid arthritis	0.00302	0.015	CbGbCtD
Nilotinib—ABCB1—Dexamethasone—rheumatoid arthritis	0.00297	0.0148	CbGbCtD
Nilotinib—CYP3A4—Hydrocortisone—rheumatoid arthritis	0.00286	0.0143	CbGbCtD
Nilotinib—CYP3A4—Prednisone—rheumatoid arthritis	0.00285	0.0142	CbGbCtD
Nilotinib—Imatinib—PIP4K2C—rheumatoid arthritis	0.00281	0.945	CrCbGaD
Nilotinib—CYP2D6—Dexamethasone—rheumatoid arthritis	0.0028	0.0139	CbGbCtD
Nilotinib—CYP3A4—Cyclosporine—rheumatoid arthritis	0.0027	0.0135	CbGbCtD
Nilotinib—CA6—saliva—rheumatoid arthritis	0.00245	0.0442	CbGeAlD
Nilotinib—ABCB1—Methotrexate—rheumatoid arthritis	0.00238	0.0119	CbGbCtD
Nilotinib—CYP3A4—Dexamethasone—rheumatoid arthritis	0.00178	0.00887	CbGbCtD
Nilotinib—MAPK8—exocrine gland—rheumatoid arthritis	0.00173	0.0311	CbGeAlD
Nilotinib—CA6—exocrine gland—rheumatoid arthritis	0.00124	0.0224	CbGeAlD
Nilotinib—MAPK8—connective tissue—rheumatoid arthritis	0.000791	0.0143	CbGeAlD
Nilotinib—FRK—lymphoid tissue—rheumatoid arthritis	0.000758	0.0137	CbGeAlD
Nilotinib—BLK—lymphoid tissue—rheumatoid arthritis	0.000731	0.0132	CbGeAlD
Nilotinib—LYN—connective tissue—rheumatoid arthritis	0.00073	0.0132	CbGeAlD
Nilotinib—EPHB2—lymphoid tissue—rheumatoid arthritis	0.000723	0.0131	CbGeAlD
Nilotinib—KIT—exocrine gland—rheumatoid arthritis	0.00072	0.013	CbGeAlD
Nilotinib—EPHB2—digestive system—rheumatoid arthritis	0.000714	0.0129	CbGeAlD
Nilotinib—EPHB3—saliva-secreting gland—rheumatoid arthritis	0.00071	0.0128	CbGeAlD
Nilotinib—CA6—parotid gland—rheumatoid arthritis	0.000645	0.0117	CbGeAlD
Nilotinib—CDC42BPB—digestive system—rheumatoid arthritis	0.000631	0.0114	CbGeAlD
Nilotinib—CA6—saliva-secreting gland—rheumatoid arthritis	0.000618	0.0112	CbGeAlD
Nilotinib—CA3—parotid gland—rheumatoid arthritis	0.000611	0.011	CbGeAlD
Nilotinib—CDC42BPB—tendon—rheumatoid arthritis	0.000601	0.0108	CbGeAlD
Nilotinib—MAPK8—lymphoid tissue—rheumatoid arthritis	0.000578	0.0104	CbGeAlD
Nilotinib—MAPK8—digestive system—rheumatoid arthritis	0.000571	0.0103	CbGeAlD
Nilotinib—MAPK8—tendon—rheumatoid arthritis	0.000543	0.00981	CbGeAlD
Nilotinib—EPHB4—parotid gland—rheumatoid arthritis	0.000541	0.00976	CbGeAlD
Nilotinib—CA3—connective tissue—rheumatoid arthritis	0.000538	0.00971	CbGeAlD
Nilotinib—LYN—lymphoid tissue—rheumatoid arthritis	0.000533	0.00963	CbGeAlD
Nilotinib—EPHA2—parotid gland—rheumatoid arthritis	0.000531	0.00958	CbGeAlD
Nilotinib—MAP4K1—lymphoid tissue—rheumatoid arthritis	0.000525	0.00948	CbGeAlD
Nilotinib—EPHB4—saliva-secreting gland—rheumatoid arthritis	0.000518	0.00935	CbGeAlD
Nilotinib—EPHA2—saliva-secreting gland—rheumatoid arthritis	0.000508	0.00917	CbGeAlD
Nilotinib—MAPK14—connective tissue—rheumatoid arthritis	0.000502	0.00906	CbGeAlD
Nilotinib—EPHB6—parotid gland—rheumatoid arthritis	0.000495	0.00893	CbGeAlD
Nilotinib—MAP4K1—tendon—rheumatoid arthritis	0.000494	0.00892	CbGeAlD
Nilotinib—EPHB4—connective tissue—rheumatoid arthritis	0.000476	0.00859	CbGeAlD
Nilotinib—EPHB6—saliva-secreting gland—rheumatoid arthritis	0.000474	0.00855	CbGeAlD
Nilotinib—EPHB3—digestive system—rheumatoid arthritis	0.000471	0.0085	CbGeAlD
Nilotinib—TEK—connective tissue—rheumatoid arthritis	0.000455	0.00822	CbGeAlD
Nilotinib—BRAF—tendon—rheumatoid arthritis	0.000452	0.00815	CbGeAlD
Nilotinib—HCK—lymphoid tissue—rheumatoid arthritis	0.000438	0.00791	CbGeAlD
Nilotinib—HCK—digestive system—rheumatoid arthritis	0.000433	0.00781	CbGeAlD
Nilotinib—CA2—exocrine gland—rheumatoid arthritis	0.000427	0.0077	CbGeAlD
Nilotinib—CA7—digestive system—rheumatoid arthritis	0.000423	0.00764	CbGeAlD
Nilotinib—MAP2K5—parotid gland—rheumatoid arthritis	0.000423	0.00764	CbGeAlD
Nilotinib—PDGFRA—connective tissue—rheumatoid arthritis	0.000413	0.00745	CbGeAlD
Nilotinib—HCK—tendon—rheumatoid arthritis	0.000412	0.00743	CbGeAlD
Nilotinib—ABL2—tendon—rheumatoid arthritis	0.000409	0.00739	CbGeAlD
Nilotinib—MAP2K5—saliva-secreting gland—rheumatoid arthritis	0.000405	0.00731	CbGeAlD
Nilotinib—CA12—connective tissue—rheumatoid arthritis	0.000381	0.00688	CbGeAlD
Nilotinib—KIT—parotid gland—rheumatoid arthritis	0.000375	0.00677	CbGeAlD
Nilotinib—EPHA4—tendon—rheumatoid arthritis	0.000374	0.00676	CbGeAlD
Nilotinib—CA9—digestive system—rheumatoid arthritis	0.000372	0.00671	CbGeAlD
Nilotinib—CA3—tendon—rheumatoid arthritis	0.00037	0.00667	CbGeAlD
Nilotinib—MAPK14—lymphoid tissue—rheumatoid arthritis	0.000367	0.00663	CbGeAlD
Nilotinib—PDGFRB—parotid gland—rheumatoid arthritis	0.000366	0.00661	CbGeAlD
Nilotinib—FGR—lymphoid tissue—rheumatoid arthritis	0.000366	0.0066	CbGeAlD
Nilotinib—CSF1R—connective tissue—rheumatoid arthritis	0.000363	0.00656	CbGeAlD
Nilotinib—MAPK14—digestive system—rheumatoid arthritis	0.000363	0.00655	CbGeAlD
Nilotinib—FGR—digestive system—rheumatoid arthritis	0.000361	0.00652	CbGeAlD
Nilotinib—KIT—saliva-secreting gland—rheumatoid arthritis	0.000359	0.00648	CbGeAlD
Nilotinib—CA9—tendon—rheumatoid arthritis	0.000354	0.00639	CbGeAlD
Nilotinib—PDGFRB—saliva-secreting gland—rheumatoid arthritis	0.000351	0.00633	CbGeAlD
Nilotinib—MAPK14—tendon—rheumatoid arthritis	0.000345	0.00623	CbGeAlD
Nilotinib—EPHB4—digestive system—rheumatoid arthritis	0.000344	0.00621	CbGeAlD
Nilotinib—FGR—tendon—rheumatoid arthritis	0.000344	0.0062	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Methylprednisolone—rheumatoid arthritis	0.000342	0.174	CbGdCrCtD
Nilotinib—EPHA2—lymphoid tissue—rheumatoid arthritis	0.000341	0.00616	CbGeAlD
Nilotinib—EPHA2—digestive system—rheumatoid arthritis	0.000337	0.00609	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Betamethasone—rheumatoid arthritis	0.000337	0.172	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Dexamethasone—rheumatoid arthritis	0.000337	0.172	CbGdCrCtD
Nilotinib—CA14—tendon—rheumatoid arthritis	0.000336	0.00606	CbGeAlD
Nilotinib—TEK—lymphoid tissue—rheumatoid arthritis	0.000333	0.00601	CbGeAlD
Nilotinib—KIT—connective tissue—rheumatoid arthritis	0.00033	0.00596	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Triamcinolone—rheumatoid arthritis	0.000329	0.168	CbGdCrCtD
Nilotinib—EPHB4—tendon—rheumatoid arthritis	0.000327	0.00591	CbGeAlD
Nilotinib—ABL1—parotid gland—rheumatoid arthritis	0.000326	0.00589	CbGeAlD
Nilotinib—PDGFRB—connective tissue—rheumatoid arthritis	0.000322	0.00582	CbGeAlD
Nilotinib—EPHA2—tendon—rheumatoid arthritis	0.000321	0.00579	CbGeAlD
Nilotinib—TEK—tendon—rheumatoid arthritis	0.000313	0.00565	CbGeAlD
Nilotinib—ABL1—saliva-secreting gland—rheumatoid arthritis	0.000313	0.00564	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisone—rheumatoid arthritis	0.000313	0.159	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Prednisolone—rheumatoid arthritis	0.000305	0.155	CbGdCrCtD
Nilotinib—PDGFRA—lymphoid tissue—rheumatoid arthritis	0.000302	0.00545	CbGeAlD
Nilotinib—EPHB6—tendon—rheumatoid arthritis	0.000299	0.0054	CbGeAlD
Nilotinib—PDGFRA—digestive system—rheumatoid arthritis	0.000298	0.00538	CbGeAlD
Nilotinib—ABL1—connective tissue—rheumatoid arthritis	0.000287	0.00518	CbGeAlD
Nilotinib—UGT1A1—digestive system—rheumatoid arthritis	0.000284	0.00513	CbGeAlD
Nilotinib—PDGFRA—tendon—rheumatoid arthritis	0.000284	0.00512	CbGeAlD
Nilotinib—CA12—digestive system—rheumatoid arthritis	0.000275	0.00497	CbGeAlD
Nilotinib—CA4—parotid gland—rheumatoid arthritis	0.000268	0.00484	CbGeAlD
Nilotinib—CSF1R—lymphoid tissue—rheumatoid arthritis	0.000266	0.0048	CbGeAlD
Nilotinib—CSF1R—digestive system—rheumatoid arthritis	0.000262	0.00474	CbGeAlD
Nilotinib—CA4—saliva-secreting gland—rheumatoid arthritis	0.000257	0.00463	CbGeAlD
Nilotinib—MAP2K5—tendon—rheumatoid arthritis	0.000256	0.00462	CbGeAlD
Nilotinib—CSF1R—tendon—rheumatoid arthritis	0.00025	0.00451	CbGeAlD
Nilotinib—KIT—lymphoid tissue—rheumatoid arthritis	0.000241	0.00435	CbGeAlD
Nilotinib—KIT—digestive system—rheumatoid arthritis	0.000238	0.0043	CbGeAlD
Nilotinib—PDGFRB—lymphoid tissue—rheumatoid arthritis	0.000236	0.00425	CbGeAlD
Nilotinib—PDGFRB—digestive system—rheumatoid arthritis	0.000233	0.0042	CbGeAlD
Nilotinib—CA2—parotid gland—rheumatoid arthritis	0.000222	0.00401	CbGeAlD
Nilotinib—PDGFRB—tendon—rheumatoid arthritis	0.000221	0.004	CbGeAlD
Nilotinib—CA1—lymphoid tissue—rheumatoid arthritis	0.000221	0.00398	CbGeAlD
Nilotinib—CA1—digestive system—rheumatoid arthritis	0.000218	0.00393	CbGeAlD
Nilotinib—CA2—saliva-secreting gland—rheumatoid arthritis	0.000213	0.00384	CbGeAlD
Nilotinib—ABL1—lymphoid tissue—rheumatoid arthritis	0.00021	0.00379	CbGeAlD
Nilotinib—ABL1—digestive system—rheumatoid arthritis	0.000207	0.00374	CbGeAlD
Nilotinib—ABCG2—parotid gland—rheumatoid arthritis	0.000206	0.00372	CbGeAlD
Nilotinib—ABL1—tendon—rheumatoid arthritis	0.000197	0.00356	CbGeAlD
Nilotinib—ABCG2—saliva-secreting gland—rheumatoid arthritis	0.000197	0.00356	CbGeAlD
Nilotinib—CA2—connective tissue—rheumatoid arthritis	0.000196	0.00353	CbGeAlD
Nilotinib—CA4—digestive system—rheumatoid arthritis	0.00017	0.00308	CbGeAlD
Nilotinib—Imatinib—ALB—rheumatoid arthritis	0.000165	0.0552	CrCbGaD
Nilotinib—CA4—tendon—rheumatoid arthritis	0.000162	0.00293	CbGeAlD
Nilotinib—CA2—lymphoid tissue—rheumatoid arthritis	0.000143	0.00258	CbGeAlD
Nilotinib—CA2—digestive system—rheumatoid arthritis	0.000141	0.00255	CbGeAlD
Nilotinib—CA2—tendon—rheumatoid arthritis	0.000134	0.00243	CbGeAlD
Nilotinib—CYP2B6—lymphoid tissue—rheumatoid arthritis	0.000122	0.00221	CbGeAlD
Nilotinib—CYP2B6—digestive system—rheumatoid arthritis	0.000121	0.00218	CbGeAlD
Nilotinib—CYP2C9—digestive system—rheumatoid arthritis	0.000119	0.00216	CbGeAlD
Nilotinib—CYP3A4—digestive system—rheumatoid arthritis	9.11e-05	0.00164	CbGeAlD
Nilotinib—CYP2D6—digestive system—rheumatoid arthritis	8.97e-05	0.00162	CbGeAlD
Nilotinib—ABCB1—lymphoid tissue—rheumatoid arthritis	6.53e-05	0.00118	CbGeAlD
Nilotinib—ABCB1—digestive system—rheumatoid arthritis	6.45e-05	0.00116	CbGeAlD
Nilotinib—Discomfort—Betamethasone—rheumatoid arthritis	3.97e-05	0.000307	CcSEcCtD
Nilotinib—Dyspepsia—Hydrocortisone—rheumatoid arthritis	3.97e-05	0.000307	CcSEcCtD
Nilotinib—Haemoglobin—Methotrexate—rheumatoid arthritis	3.96e-05	0.000307	CcSEcCtD
Nilotinib—Hypotension—Methylprednisolone—rheumatoid arthritis	3.96e-05	0.000307	CcSEcCtD
Nilotinib—Pain—Prednisolone—rheumatoid arthritis	3.95e-05	0.000306	CcSEcCtD
Nilotinib—Haemorrhage—Methotrexate—rheumatoid arthritis	3.94e-05	0.000306	CcSEcCtD
Nilotinib—Hepatitis—Methotrexate—rheumatoid arthritis	3.94e-05	0.000306	CcSEcCtD
Nilotinib—Decreased appetite—Hydrocortisone—rheumatoid arthritis	3.92e-05	0.000304	CcSEcCtD
Nilotinib—Pharyngitis—Methotrexate—rheumatoid arthritis	3.91e-05	0.000303	CcSEcCtD
Nilotinib—Nausea—Leflunomide—rheumatoid arthritis	3.9e-05	0.000302	CcSEcCtD
Nilotinib—Urinary tract disorder—Methotrexate—rheumatoid arthritis	3.89e-05	0.000302	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Hydrocortisone—rheumatoid arthritis	3.89e-05	0.000301	CcSEcCtD
Nilotinib—Fatigue—Hydrocortisone—rheumatoid arthritis	3.88e-05	0.000301	CcSEcCtD
Nilotinib—Vision blurred—Prednisone—rheumatoid arthritis	3.87e-05	0.0003	CcSEcCtD
Nilotinib—Urethral disorder—Methotrexate—rheumatoid arthritis	3.87e-05	0.0003	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Triamcinolone—rheumatoid arthritis	3.87e-05	0.0003	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methylprednisolone—rheumatoid arthritis	3.86e-05	0.000299	CcSEcCtD
Nilotinib—Pain—Hydrocortisone—rheumatoid arthritis	3.85e-05	0.000299	CcSEcCtD
Nilotinib—Oedema—Dexamethasone—rheumatoid arthritis	3.85e-05	0.000298	CcSEcCtD
Nilotinib—Oedema—Betamethasone—rheumatoid arthritis	3.85e-05	0.000298	CcSEcCtD
Nilotinib—Insomnia—Triamcinolone—rheumatoid arthritis	3.84e-05	0.000297	CcSEcCtD
Nilotinib—Insomnia—Methylprednisolone—rheumatoid arthritis	3.83e-05	0.000297	CcSEcCtD
Nilotinib—Infection—Dexamethasone—rheumatoid arthritis	3.82e-05	0.000296	CcSEcCtD
Nilotinib—Infection—Betamethasone—rheumatoid arthritis	3.82e-05	0.000296	CcSEcCtD
Nilotinib—Ill-defined disorder—Prednisone—rheumatoid arthritis	3.81e-05	0.000295	CcSEcCtD
Nilotinib—Paraesthesia—Triamcinolone—rheumatoid arthritis	3.81e-05	0.000295	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisolone—rheumatoid arthritis	3.8e-05	0.000295	CcSEcCtD
Nilotinib—Paraesthesia—Methylprednisolone—rheumatoid arthritis	3.8e-05	0.000295	CcSEcCtD
Nilotinib—Visual impairment—Methotrexate—rheumatoid arthritis	3.8e-05	0.000295	CcSEcCtD
Nilotinib—Anaemia—Prednisone—rheumatoid arthritis	3.8e-05	0.000294	CcSEcCtD
Nilotinib—Shock—Betamethasone—rheumatoid arthritis	3.79e-05	0.000293	CcSEcCtD
Nilotinib—Shock—Dexamethasone—rheumatoid arthritis	3.79e-05	0.000293	CcSEcCtD
Nilotinib—Dyspnoea—Triamcinolone—rheumatoid arthritis	3.78e-05	0.000293	CcSEcCtD
Nilotinib—Nervous system disorder—Betamethasone—rheumatoid arthritis	3.78e-05	0.000293	CcSEcCtD
Nilotinib—Nervous system disorder—Dexamethasone—rheumatoid arthritis	3.78e-05	0.000293	CcSEcCtD
Nilotinib—Thrombocytopenia—Dexamethasone—rheumatoid arthritis	3.77e-05	0.000292	CcSEcCtD
Nilotinib—Thrombocytopenia—Betamethasone—rheumatoid arthritis	3.77e-05	0.000292	CcSEcCtD
Nilotinib—Tachycardia—Betamethasone—rheumatoid arthritis	3.76e-05	0.000291	CcSEcCtD
Nilotinib—Tachycardia—Dexamethasone—rheumatoid arthritis	3.76e-05	0.000291	CcSEcCtD
Nilotinib—Hypersensitivity—Cyclosporine—rheumatoid arthritis	3.74e-05	0.000289	CcSEcCtD
Nilotinib—Dyspepsia—Triamcinolone—rheumatoid arthritis	3.73e-05	0.000289	CcSEcCtD
Nilotinib—Erythema multiforme—Methotrexate—rheumatoid arthritis	3.73e-05	0.000289	CcSEcCtD
Nilotinib—Dyspepsia—Methylprednisolone—rheumatoid arthritis	3.73e-05	0.000289	CcSEcCtD
Nilotinib—Hyperhidrosis—Dexamethasone—rheumatoid arthritis	3.72e-05	0.000288	CcSEcCtD
Nilotinib—Hyperhidrosis—Betamethasone—rheumatoid arthritis	3.72e-05	0.000288	CcSEcCtD
Nilotinib—Feeling abnormal—Hydrocortisone—rheumatoid arthritis	3.71e-05	0.000288	CcSEcCtD
Nilotinib—Malaise—Prednisone—rheumatoid arthritis	3.7e-05	0.000287	CcSEcCtD
Nilotinib—Vertigo—Prednisone—rheumatoid arthritis	3.69e-05	0.000286	CcSEcCtD
Nilotinib—Eye disorder—Methotrexate—rheumatoid arthritis	3.69e-05	0.000286	CcSEcCtD
Nilotinib—Gastrointestinal pain—Hydrocortisone—rheumatoid arthritis	3.68e-05	0.000286	CcSEcCtD
Nilotinib—Syncope—Prednisone—rheumatoid arthritis	3.68e-05	0.000285	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—rheumatoid arthritis	3.68e-05	0.000285	CcSEcCtD
Nilotinib—Anorexia—Dexamethasone—rheumatoid arthritis	3.67e-05	0.000284	CcSEcCtD
Nilotinib—Anorexia—Betamethasone—rheumatoid arthritis	3.67e-05	0.000284	CcSEcCtD
Nilotinib—Urticaria—Prednisolone—rheumatoid arthritis	3.66e-05	0.000284	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—rheumatoid arthritis	3.66e-05	0.000284	CcSEcCtD
Nilotinib—Fatigue—Triamcinolone—rheumatoid arthritis	3.66e-05	0.000283	CcSEcCtD
Nilotinib—Fatigue—Methylprednisolone—rheumatoid arthritis	3.65e-05	0.000283	CcSEcCtD
Nilotinib—Asthenia—Cyclosporine—rheumatoid arthritis	3.64e-05	0.000282	CcSEcCtD
Nilotinib—Pain—Triamcinolone—rheumatoid arthritis	3.63e-05	0.000281	CcSEcCtD
Nilotinib—Loss of consciousness—Prednisone—rheumatoid arthritis	3.61e-05	0.00028	CcSEcCtD
Nilotinib—Hypotension—Betamethasone—rheumatoid arthritis	3.6e-05	0.000279	CcSEcCtD
Nilotinib—Hypotension—Dexamethasone—rheumatoid arthritis	3.6e-05	0.000279	CcSEcCtD
Nilotinib—Pruritus—Cyclosporine—rheumatoid arthritis	3.59e-05	0.000278	CcSEcCtD
Nilotinib—Urticaria—Hydrocortisone—rheumatoid arthritis	3.58e-05	0.000277	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—rheumatoid arthritis	3.58e-05	0.000277	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—rheumatoid arthritis	3.56e-05	0.000276	CcSEcCtD
Nilotinib—Body temperature increased—Hydrocortisone—rheumatoid arthritis	3.56e-05	0.000276	CcSEcCtD
Nilotinib—Abdominal pain—Hydrocortisone—rheumatoid arthritis	3.56e-05	0.000276	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—rheumatoid arthritis	3.55e-05	0.000275	CcSEcCtD
Nilotinib—Hypertension—Prednisone—rheumatoid arthritis	3.55e-05	0.000275	CcSEcCtD
Nilotinib—Chills—Methotrexate—rheumatoid arthritis	3.54e-05	0.000274	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Dexamethasone—rheumatoid arthritis	3.51e-05	0.000272	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Betamethasone—rheumatoid arthritis	3.51e-05	0.000272	CcSEcCtD
Nilotinib—Myalgia—Prednisone—rheumatoid arthritis	3.5e-05	0.000271	CcSEcCtD
Nilotinib—Arthralgia—Prednisone—rheumatoid arthritis	3.5e-05	0.000271	CcSEcCtD
Nilotinib—Feeling abnormal—Triamcinolone—rheumatoid arthritis	3.5e-05	0.000271	CcSEcCtD
Nilotinib—Feeling abnormal—Methylprednisolone—rheumatoid arthritis	3.49e-05	0.00027	CcSEcCtD
Nilotinib—Anxiety—Prednisone—rheumatoid arthritis	3.48e-05	0.00027	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—rheumatoid arthritis	3.48e-05	0.00027	CcSEcCtD
Nilotinib—Insomnia—Betamethasone—rheumatoid arthritis	3.48e-05	0.00027	CcSEcCtD
Nilotinib—Insomnia—Dexamethasone—rheumatoid arthritis	3.48e-05	0.00027	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—rheumatoid arthritis	3.47e-05	0.000269	CcSEcCtD
Nilotinib—Diarrhoea—Cyclosporine—rheumatoid arthritis	3.47e-05	0.000269	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methylprednisolone—rheumatoid arthritis	3.46e-05	0.000268	CcSEcCtD
Nilotinib—Paraesthesia—Dexamethasone—rheumatoid arthritis	3.46e-05	0.000268	CcSEcCtD
Nilotinib—Paraesthesia—Betamethasone—rheumatoid arthritis	3.46e-05	0.000268	CcSEcCtD
Nilotinib—Discomfort—Prednisone—rheumatoid arthritis	3.46e-05	0.000268	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—rheumatoid arthritis	3.45e-05	0.000268	CcSEcCtD
Nilotinib—Erythema—Methotrexate—rheumatoid arthritis	3.43e-05	0.000266	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—rheumatoid arthritis	3.43e-05	0.000266	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisolone—rheumatoid arthritis	3.4e-05	0.000263	CcSEcCtD
Nilotinib—Dyspepsia—Dexamethasone—rheumatoid arthritis	3.39e-05	0.000263	CcSEcCtD
Nilotinib—Dyspepsia—Betamethasone—rheumatoid arthritis	3.39e-05	0.000263	CcSEcCtD
Nilotinib—Urticaria—Triamcinolone—rheumatoid arthritis	3.37e-05	0.000261	CcSEcCtD
Nilotinib—Urticaria—Methylprednisolone—rheumatoid arthritis	3.36e-05	0.000261	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—rheumatoid arthritis	3.36e-05	0.000261	CcSEcCtD
Nilotinib—Body temperature increased—Triamcinolone—rheumatoid arthritis	3.35e-05	0.00026	CcSEcCtD
Nilotinib—Dizziness—Cyclosporine—rheumatoid arthritis	3.35e-05	0.00026	CcSEcCtD
Nilotinib—Oedema—Prednisone—rheumatoid arthritis	3.35e-05	0.00026	CcSEcCtD
Nilotinib—Abdominal pain—Methylprednisolone—rheumatoid arthritis	3.35e-05	0.000259	CcSEcCtD
Nilotinib—Decreased appetite—Dexamethasone—rheumatoid arthritis	3.35e-05	0.000259	CcSEcCtD
Nilotinib—Decreased appetite—Betamethasone—rheumatoid arthritis	3.35e-05	0.000259	CcSEcCtD
Nilotinib—Infection—Prednisone—rheumatoid arthritis	3.33e-05	0.000258	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Betamethasone—rheumatoid arthritis	3.32e-05	0.000258	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Dexamethasone—rheumatoid arthritis	3.32e-05	0.000258	CcSEcCtD
Nilotinib—Back pain—Methotrexate—rheumatoid arthritis	3.32e-05	0.000257	CcSEcCtD
Nilotinib—Hypersensitivity—Hydrocortisone—rheumatoid arthritis	3.32e-05	0.000257	CcSEcCtD
Nilotinib—Fatigue—Dexamethasone—rheumatoid arthritis	3.32e-05	0.000257	CcSEcCtD
Nilotinib—Fatigue—Betamethasone—rheumatoid arthritis	3.32e-05	0.000257	CcSEcCtD
Nilotinib—Shock—Prednisone—rheumatoid arthritis	3.3e-05	0.000256	CcSEcCtD
Nilotinib—Pain—Betamethasone—rheumatoid arthritis	3.29e-05	0.000255	CcSEcCtD
Nilotinib—Pain—Dexamethasone—rheumatoid arthritis	3.29e-05	0.000255	CcSEcCtD
Nilotinib—Nervous system disorder—Prednisone—rheumatoid arthritis	3.29e-05	0.000255	CcSEcCtD
Nilotinib—Tachycardia—Prednisone—rheumatoid arthritis	3.27e-05	0.000254	CcSEcCtD
Nilotinib—Skin disorder—Prednisone—rheumatoid arthritis	3.26e-05	0.000252	CcSEcCtD
Nilotinib—Hyperhidrosis—Prednisone—rheumatoid arthritis	3.24e-05	0.000251	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—rheumatoid arthritis	3.24e-05	0.000251	CcSEcCtD
Nilotinib—Asthenia—Hydrocortisone—rheumatoid arthritis	3.23e-05	0.000251	CcSEcCtD
Nilotinib—Vomiting—Cyclosporine—rheumatoid arthritis	3.22e-05	0.00025	CcSEcCtD
Nilotinib—Rash—Cyclosporine—rheumatoid arthritis	3.2e-05	0.000248	CcSEcCtD
Nilotinib—Anorexia—Prednisone—rheumatoid arthritis	3.2e-05	0.000248	CcSEcCtD
Nilotinib—Dermatitis—Cyclosporine—rheumatoid arthritis	3.19e-05	0.000247	CcSEcCtD
Nilotinib—Pruritus—Hydrocortisone—rheumatoid arthritis	3.19e-05	0.000247	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—rheumatoid arthritis	3.19e-05	0.000247	CcSEcCtD
Nilotinib—Headache—Cyclosporine—rheumatoid arthritis	3.18e-05	0.000246	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—rheumatoid arthritis	3.17e-05	0.000246	CcSEcCtD
Nilotinib—Feeling abnormal—Betamethasone—rheumatoid arthritis	3.17e-05	0.000246	CcSEcCtD
Nilotinib—Feeling abnormal—Dexamethasone—rheumatoid arthritis	3.17e-05	0.000246	CcSEcCtD
Nilotinib—Gastrointestinal pain—Dexamethasone—rheumatoid arthritis	3.15e-05	0.000244	CcSEcCtD
Nilotinib—Gastrointestinal pain—Betamethasone—rheumatoid arthritis	3.15e-05	0.000244	CcSEcCtD
Nilotinib—Hypersensitivity—Triamcinolone—rheumatoid arthritis	3.13e-05	0.000242	CcSEcCtD
Nilotinib—Hypersensitivity—Methylprednisolone—rheumatoid arthritis	3.12e-05	0.000242	CcSEcCtD
Nilotinib—Malaise—Methotrexate—rheumatoid arthritis	3.1e-05	0.00024	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—rheumatoid arthritis	3.08e-05	0.000239	CcSEcCtD
Nilotinib—Diarrhoea—Hydrocortisone—rheumatoid arthritis	3.08e-05	0.000239	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—rheumatoid arthritis	3.07e-05	0.000238	CcSEcCtD
Nilotinib—Urticaria—Betamethasone—rheumatoid arthritis	3.06e-05	0.000237	CcSEcCtD
Nilotinib—Urticaria—Dexamethasone—rheumatoid arthritis	3.06e-05	0.000237	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Prednisone—rheumatoid arthritis	3.05e-05	0.000237	CcSEcCtD
Nilotinib—Dizziness—Prednisolone—rheumatoid arthritis	3.05e-05	0.000236	CcSEcCtD
Nilotinib—Asthenia—Triamcinolone—rheumatoid arthritis	3.04e-05	0.000236	CcSEcCtD
Nilotinib—Abdominal pain—Betamethasone—rheumatoid arthritis	3.04e-05	0.000236	CcSEcCtD
Nilotinib—Abdominal pain—Dexamethasone—rheumatoid arthritis	3.04e-05	0.000236	CcSEcCtD
Nilotinib—Body temperature increased—Dexamethasone—rheumatoid arthritis	3.04e-05	0.000236	CcSEcCtD
Nilotinib—Body temperature increased—Betamethasone—rheumatoid arthritis	3.04e-05	0.000236	CcSEcCtD
Nilotinib—Asthenia—Methylprednisolone—rheumatoid arthritis	3.04e-05	0.000235	CcSEcCtD
Nilotinib—Insomnia—Prednisone—rheumatoid arthritis	3.03e-05	0.000235	CcSEcCtD
Nilotinib—Nausea—Cyclosporine—rheumatoid arthritis	3.01e-05	0.000233	CcSEcCtD
Nilotinib—Paraesthesia—Prednisone—rheumatoid arthritis	3.01e-05	0.000233	CcSEcCtD
Nilotinib—Pruritus—Triamcinolone—rheumatoid arthritis	3e-05	0.000233	CcSEcCtD
Nilotinib—Cough—Methotrexate—rheumatoid arthritis	3e-05	0.000232	CcSEcCtD
Nilotinib—Pruritus—Methylprednisolone—rheumatoid arthritis	2.99e-05	0.000232	CcSEcCtD
Nilotinib—Dizziness—Hydrocortisone—rheumatoid arthritis	2.98e-05	0.000231	CcSEcCtD
Nilotinib—Dyspepsia—Prednisone—rheumatoid arthritis	2.95e-05	0.000229	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—rheumatoid arthritis	2.92e-05	0.000226	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—rheumatoid arthritis	2.92e-05	0.000226	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—rheumatoid arthritis	2.92e-05	0.000226	CcSEcCtD
Nilotinib—Decreased appetite—Prednisone—rheumatoid arthritis	2.91e-05	0.000226	CcSEcCtD
Nilotinib—Rash—Prednisolone—rheumatoid arthritis	2.91e-05	0.000225	CcSEcCtD
Nilotinib—Dermatitis—Prednisolone—rheumatoid arthritis	2.91e-05	0.000225	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—rheumatoid arthritis	2.9e-05	0.000225	CcSEcCtD
Nilotinib—Diarrhoea—Methylprednisolone—rheumatoid arthritis	2.9e-05	0.000224	CcSEcCtD
Nilotinib—Fatigue—Prednisone—rheumatoid arthritis	2.89e-05	0.000224	CcSEcCtD
Nilotinib—Headache—Prednisolone—rheumatoid arthritis	2.89e-05	0.000224	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—rheumatoid arthritis	2.89e-05	0.000224	CcSEcCtD
Nilotinib—Constipation—Prednisone—rheumatoid arthritis	2.87e-05	0.000222	CcSEcCtD
Nilotinib—Vomiting—Hydrocortisone—rheumatoid arthritis	2.86e-05	0.000222	CcSEcCtD
Nilotinib—Rash—Hydrocortisone—rheumatoid arthritis	2.84e-05	0.00022	CcSEcCtD
Nilotinib—Dermatitis—Hydrocortisone—rheumatoid arthritis	2.84e-05	0.00022	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—rheumatoid arthritis	2.82e-05	0.000219	CcSEcCtD
Nilotinib—Headache—Hydrocortisone—rheumatoid arthritis	2.82e-05	0.000219	CcSEcCtD
Nilotinib—Dizziness—Triamcinolone—rheumatoid arthritis	2.81e-05	0.000217	CcSEcCtD
Nilotinib—Dizziness—Methylprednisolone—rheumatoid arthritis	2.8e-05	0.000217	CcSEcCtD
Nilotinib—Infection—Methotrexate—rheumatoid arthritis	2.78e-05	0.000216	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisone—rheumatoid arthritis	2.76e-05	0.000214	CcSEcCtD
Nilotinib—Asthenia—Betamethasone—rheumatoid arthritis	2.76e-05	0.000214	CcSEcCtD
Nilotinib—Asthenia—Dexamethasone—rheumatoid arthritis	2.76e-05	0.000214	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—rheumatoid arthritis	2.75e-05	0.000213	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—rheumatoid arthritis	2.74e-05	0.000213	CcSEcCtD
Nilotinib—Gastrointestinal pain—Prednisone—rheumatoid arthritis	2.74e-05	0.000212	CcSEcCtD
Nilotinib—Nausea—Prednisolone—rheumatoid arthritis	2.74e-05	0.000212	CcSEcCtD
Nilotinib—Pruritus—Betamethasone—rheumatoid arthritis	2.72e-05	0.000211	CcSEcCtD
Nilotinib—Pruritus—Dexamethasone—rheumatoid arthritis	2.72e-05	0.000211	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—rheumatoid arthritis	2.72e-05	0.000211	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—rheumatoid arthritis	2.71e-05	0.00021	CcSEcCtD
Nilotinib—Vomiting—Triamcinolone—rheumatoid arthritis	2.7e-05	0.000209	CcSEcCtD
Nilotinib—Vomiting—Methylprednisolone—rheumatoid arthritis	2.69e-05	0.000209	CcSEcCtD
Nilotinib—Nausea—Hydrocortisone—rheumatoid arthritis	2.68e-05	0.000207	CcSEcCtD
Nilotinib—Rash—Triamcinolone—rheumatoid arthritis	2.68e-05	0.000207	CcSEcCtD
Nilotinib—Dermatitis—Triamcinolone—rheumatoid arthritis	2.67e-05	0.000207	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—rheumatoid arthritis	2.67e-05	0.000207	CcSEcCtD
Nilotinib—Rash—Methylprednisolone—rheumatoid arthritis	2.67e-05	0.000207	CcSEcCtD
Nilotinib—Dermatitis—Methylprednisolone—rheumatoid arthritis	2.67e-05	0.000207	CcSEcCtD
Nilotinib—Urticaria—Prednisone—rheumatoid arthritis	2.66e-05	0.000206	CcSEcCtD
Nilotinib—Headache—Triamcinolone—rheumatoid arthritis	2.66e-05	0.000206	CcSEcCtD
Nilotinib—Headache—Methylprednisolone—rheumatoid arthritis	2.65e-05	0.000206	CcSEcCtD
Nilotinib—Abdominal pain—Prednisone—rheumatoid arthritis	2.65e-05	0.000205	CcSEcCtD
Nilotinib—Body temperature increased—Prednisone—rheumatoid arthritis	2.65e-05	0.000205	CcSEcCtD
Nilotinib—Diarrhoea—Dexamethasone—rheumatoid arthritis	2.63e-05	0.000204	CcSEcCtD
Nilotinib—Diarrhoea—Betamethasone—rheumatoid arthritis	2.63e-05	0.000204	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—rheumatoid arthritis	2.62e-05	0.000203	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—rheumatoid arthritis	2.55e-05	0.000198	CcSEcCtD
Nilotinib—Dizziness—Betamethasone—rheumatoid arthritis	2.55e-05	0.000197	CcSEcCtD
Nilotinib—Dizziness—Dexamethasone—rheumatoid arthritis	2.55e-05	0.000197	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—rheumatoid arthritis	2.53e-05	0.000196	CcSEcCtD
Nilotinib—Nausea—Triamcinolone—rheumatoid arthritis	2.52e-05	0.000195	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—rheumatoid arthritis	2.52e-05	0.000195	CcSEcCtD
Nilotinib—Nausea—Methylprednisolone—rheumatoid arthritis	2.51e-05	0.000195	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—rheumatoid arthritis	2.5e-05	0.000194	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisone—rheumatoid arthritis	2.47e-05	0.000191	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—rheumatoid arthritis	2.47e-05	0.000191	CcSEcCtD
Nilotinib—Vomiting—Dexamethasone—rheumatoid arthritis	2.45e-05	0.00019	CcSEcCtD
Nilotinib—Vomiting—Betamethasone—rheumatoid arthritis	2.45e-05	0.00019	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—rheumatoid arthritis	2.44e-05	0.000189	CcSEcCtD
Nilotinib—Rash—Betamethasone—rheumatoid arthritis	2.43e-05	0.000188	CcSEcCtD
Nilotinib—Rash—Dexamethasone—rheumatoid arthritis	2.43e-05	0.000188	CcSEcCtD
Nilotinib—Dermatitis—Dexamethasone—rheumatoid arthritis	2.42e-05	0.000188	CcSEcCtD
Nilotinib—Dermatitis—Betamethasone—rheumatoid arthritis	2.42e-05	0.000188	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—rheumatoid arthritis	2.42e-05	0.000187	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—rheumatoid arthritis	2.42e-05	0.000187	CcSEcCtD
Nilotinib—Headache—Dexamethasone—rheumatoid arthritis	2.41e-05	0.000187	CcSEcCtD
Nilotinib—Headache—Betamethasone—rheumatoid arthritis	2.41e-05	0.000187	CcSEcCtD
Nilotinib—Asthenia—Prednisone—rheumatoid arthritis	2.41e-05	0.000186	CcSEcCtD
Nilotinib—Pain—Methotrexate—rheumatoid arthritis	2.4e-05	0.000186	CcSEcCtD
Nilotinib—Pruritus—Prednisone—rheumatoid arthritis	2.37e-05	0.000184	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—rheumatoid arthritis	2.31e-05	0.000179	CcSEcCtD
Nilotinib—Diarrhoea—Prednisone—rheumatoid arthritis	2.29e-05	0.000178	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—rheumatoid arthritis	2.29e-05	0.000178	CcSEcCtD
Nilotinib—Nausea—Betamethasone—rheumatoid arthritis	2.29e-05	0.000177	CcSEcCtD
Nilotinib—Nausea—Dexamethasone—rheumatoid arthritis	2.29e-05	0.000177	CcSEcCtD
Nilotinib—Urticaria—Methotrexate—rheumatoid arthritis	2.23e-05	0.000172	CcSEcCtD
Nilotinib—Dizziness—Prednisone—rheumatoid arthritis	2.22e-05	0.000172	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—rheumatoid arthritis	2.21e-05	0.000172	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—rheumatoid arthritis	2.21e-05	0.000172	CcSEcCtD
Nilotinib—Vomiting—Prednisone—rheumatoid arthritis	2.13e-05	0.000165	CcSEcCtD
Nilotinib—Rash—Prednisone—rheumatoid arthritis	2.11e-05	0.000164	CcSEcCtD
Nilotinib—Dermatitis—Prednisone—rheumatoid arthritis	2.11e-05	0.000164	CcSEcCtD
Nilotinib—Headache—Prednisone—rheumatoid arthritis	2.1e-05	0.000163	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—rheumatoid arthritis	2.06e-05	0.00016	CcSEcCtD
Nilotinib—Asthenia—Methotrexate—rheumatoid arthritis	2.01e-05	0.000156	CcSEcCtD
Nilotinib—Nausea—Prednisone—rheumatoid arthritis	1.99e-05	0.000154	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—rheumatoid arthritis	1.98e-05	0.000154	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—rheumatoid arthritis	1.92e-05	0.000149	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—rheumatoid arthritis	1.85e-05	0.000144	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—rheumatoid arthritis	1.78e-05	0.000138	CcSEcCtD
Nilotinib—Rash—Methotrexate—rheumatoid arthritis	1.77e-05	0.000137	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—rheumatoid arthritis	1.76e-05	0.000137	CcSEcCtD
Nilotinib—Headache—Methotrexate—rheumatoid arthritis	1.76e-05	0.000136	CcSEcCtD
Nilotinib—Nausea—Methotrexate—rheumatoid arthritis	1.66e-05	0.000129	CcSEcCtD
Nilotinib—BRAF—Signaling Pathways—TYK2—rheumatoid arthritis	1.28e-06	8.27e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6R—rheumatoid arthritis	1.28e-06	8.26e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL2—rheumatoid arthritis	1.28e-06	8.26e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP9—rheumatoid arthritis	1.28e-06	8.25e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL5—rheumatoid arthritis	1.28e-06	8.23e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—LEP—rheumatoid arthritis	1.28e-06	8.23e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTGS2—rheumatoid arthritis	1.27e-06	8.23e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NOS3—rheumatoid arthritis	1.27e-06	8.19e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NFKB1—rheumatoid arthritis	1.26e-06	8.16e-06	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—rheumatoid arthritis	1.26e-06	8.16e-06	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—rheumatoid arthritis	1.26e-06	8.12e-06	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—rheumatoid arthritis	1.26e-06	8.12e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1B—rheumatoid arthritis	1.26e-06	8.12e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NOS3—rheumatoid arthritis	1.26e-06	8.11e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CSF2—rheumatoid arthritis	1.26e-06	8.11e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL2—rheumatoid arthritis	1.25e-06	8.08e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1B—rheumatoid arthritis	1.25e-06	8.08e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6R—rheumatoid arthritis	1.25e-06	8.07e-06	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—rheumatoid arthritis	1.25e-06	8.07e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL2—rheumatoid arthritis	1.25e-06	8.05e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—POMC—rheumatoid arthritis	1.24e-06	8.02e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—TYK2—rheumatoid arthritis	1.23e-06	7.96e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FN1—rheumatoid arthritis	1.23e-06	7.93e-06	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—rheumatoid arthritis	1.23e-06	7.92e-06	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—rheumatoid arthritis	1.23e-06	7.92e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—POMC—rheumatoid arthritis	1.23e-06	7.91e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6ST—rheumatoid arthritis	1.22e-06	7.9e-06	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—rheumatoid arthritis	1.22e-06	7.9e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCL2—rheumatoid arthritis	1.22e-06	7.84e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP9—rheumatoid arthritis	1.22e-06	7.84e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6R—rheumatoid arthritis	1.21e-06	7.82e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—LEP—rheumatoid arthritis	1.21e-06	7.8e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FN1—rheumatoid arthritis	1.2e-06	7.76e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NFKB1—rheumatoid arthritis	1.2e-06	7.76e-06	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—rheumatoid arthritis	1.2e-06	7.73e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NFKB1—rheumatoid arthritis	1.2e-06	7.73e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6ST—rheumatoid arthritis	1.2e-06	7.73e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1B—rheumatoid arthritis	1.19e-06	7.69e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL2—rheumatoid arthritis	1.19e-06	7.66e-06	CbGpPWpGaD
Nilotinib—BRAF—Disease—TGFB1—rheumatoid arthritis	1.19e-06	7.66e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MAPK8—rheumatoid arthritis	1.18e-06	7.63e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SPP1—rheumatoid arthritis	1.18e-06	7.62e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—rheumatoid arthritis	1.18e-06	7.61e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—MAPK8—rheumatoid arthritis	1.18e-06	7.6e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CD80—rheumatoid arthritis	1.18e-06	7.6e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—NFKB1—rheumatoid arthritis	1.17e-06	7.57e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ENO1—rheumatoid arthritis	1.17e-06	7.56e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NFKB1—rheumatoid arthritis	1.17e-06	7.54e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TYK2—rheumatoid arthritis	1.17e-06	7.52e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	1.16e-06	7.46e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IFNG—rheumatoid arthritis	1.16e-06	7.46e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—MAPK8—rheumatoid arthritis	1.15e-06	7.44e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CD80—rheumatoid arthritis	1.15e-06	7.44e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCR5—rheumatoid arthritis	1.15e-06	7.42e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MED1—rheumatoid arthritis	1.15e-06	7.41e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MAPK8—rheumatoid arthritis	1.15e-06	7.41e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—VEGFA—rheumatoid arthritis	1.15e-06	7.41e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NOS3—rheumatoid arthritis	1.14e-06	7.39e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CAT—rheumatoid arthritis	1.14e-06	7.37e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FN1—rheumatoid arthritis	1.14e-06	7.36e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—TYK2—rheumatoid arthritis	1.14e-06	7.35e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6ST—rheumatoid arthritis	1.14e-06	7.33e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2RA—rheumatoid arthritis	1.13e-06	7.31e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CXCL8—rheumatoid arthritis	1.13e-06	7.27e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—C3—rheumatoid arthritis	1.12e-06	7.25e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—POMC—rheumatoid arthritis	1.12e-06	7.22e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS3—rheumatoid arthritis	1.12e-06	7.22e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ALB—rheumatoid arthritis	1.12e-06	7.21e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—rheumatoid arthritis	1.12e-06	7.2e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CXCL8—rheumatoid arthritis	1.12e-06	7.2e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NFKB1—rheumatoid arthritis	1.11e-06	7.18e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TYK2—rheumatoid arthritis	1.1e-06	7.12e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ENO1—rheumatoid arthritis	1.1e-06	7.12e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—POMC—rheumatoid arthritis	1.1e-06	7.07e-06	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ALB—rheumatoid arthritis	1.1e-06	7.07e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCL2—rheumatoid arthritis	1.1e-06	7.07e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ENO1—rheumatoid arthritis	1.09e-06	7.06e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—MAPK8—rheumatoid arthritis	1.09e-06	7.05e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CD80—rheumatoid arthritis	1.09e-06	7.05e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6R—rheumatoid arthritis	1.09e-06	7.04e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—VEGFA—rheumatoid arthritis	1.09e-06	7.04e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NOS3—rheumatoid arthritis	1.08e-06	6.99e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—TGFB1—rheumatoid arthritis	1.08e-06	6.97e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2—rheumatoid arthritis	1.08e-06	6.94e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—rheumatoid arthritis	1.08e-06	6.94e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCL2—rheumatoid arthritis	1.07e-06	6.92e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—NOS3—rheumatoid arthritis	1.07e-06	6.9e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6R—rheumatoid arthritis	1.07e-06	6.9e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—B3GNT2—rheumatoid arthritis	1.07e-06	6.89e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ACP5—rheumatoid arthritis	1.07e-06	6.89e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2—rheumatoid arthritis	1.07e-06	6.88e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TGFB1—rheumatoid arthritis	1.05e-06	6.8e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—LEP—rheumatoid arthritis	1.05e-06	6.75e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—POMC—rheumatoid arthritis	1.04e-06	6.71e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—POMC—rheumatoid arthritis	1.04e-06	6.7e-06	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—rheumatoid arthritis	1.04e-06	6.69e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1B—rheumatoid arthritis	1.03e-06	6.65e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—rheumatoid arthritis	1.03e-06	6.65e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—rheumatoid arthritis	1.03e-06	6.63e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—rheumatoid arthritis	1.02e-06	6.6e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TGFB1—rheumatoid arthritis	1.02e-06	6.6e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—rheumatoid arthritis	1.02e-06	6.57e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCL2—rheumatoid arthritis	1.02e-06	6.56e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CXCL8—rheumatoid arthritis	1.02e-06	6.55e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6R—rheumatoid arthritis	1.01e-06	6.54e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—rheumatoid arthritis	1.01e-06	6.51e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NFKB1—rheumatoid arthritis	1.01e-06	6.5e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TGFB1—rheumatoid arthritis	1e-06	6.46e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NFKB1—rheumatoid arthritis	9.98e-07	6.44e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TYK2—rheumatoid arthritis	9.94e-07	6.42e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MAPK8—rheumatoid arthritis	9.9e-07	6.39e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FN1—rheumatoid arthritis	9.86e-07	6.36e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6ST—rheumatoid arthritis	9.82e-07	6.34e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MAPK8—rheumatoid arthritis	9.81e-07	6.33e-06	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—rheumatoid arthritis	9.78e-07	6.31e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—rheumatoid arthritis	9.78e-07	6.31e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NOS3—rheumatoid arthritis	9.76e-07	6.3e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TYK2—rheumatoid arthritis	9.74e-07	6.28e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—rheumatoid arthritis	9.7e-07	6.26e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CAT—rheumatoid arthritis	9.68e-07	6.24e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—NFKB1—rheumatoid arthritis	9.62e-07	6.21e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—BGN—rheumatoid arthritis	9.62e-07	6.21e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCL8—rheumatoid arthritis	9.61e-07	6.2e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NOS3—rheumatoid arthritis	9.56e-07	6.17e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—MTHFR—rheumatoid arthritis	9.54e-07	6.15e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ALB—rheumatoid arthritis	9.49e-07	6.12e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK8—rheumatoid arthritis	9.45e-07	6.1e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CD80—rheumatoid arthritis	9.45e-07	6.1e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	9.41e-07	6.07e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TYK2—rheumatoid arthritis	9.23e-07	5.96e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TGFB1—rheumatoid arthritis	9.22e-07	5.95e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—rheumatoid arthritis	9.18e-07	5.93e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—rheumatoid arthritis	9.18e-07	5.93e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—rheumatoid arthritis	9.15e-07	5.9e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NFKB1—rheumatoid arthritis	9.09e-07	5.86e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—NOS3—rheumatoid arthritis	9.08e-07	5.86e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NOS3—rheumatoid arthritis	9.06e-07	5.85e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—rheumatoid arthritis	9.06e-07	5.85e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—POMC—rheumatoid arthritis	8.98e-07	5.8e-06	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—rheumatoid arthritis	8.95e-07	5.77e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK8—rheumatoid arthritis	8.93e-07	5.76e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALOX5—rheumatoid arthritis	8.85e-07	5.71e-06	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—rheumatoid arthritis	8.82e-07	5.69e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL2—rheumatoid arthritis	8.79e-07	5.67e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6R—rheumatoid arthritis	8.76e-07	5.65e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—rheumatoid arthritis	8.69e-07	5.61e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—rheumatoid arthritis	8.67e-07	5.6e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL8—rheumatoid arthritis	8.66e-07	5.59e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NFKB1—rheumatoid arthritis	8.6e-07	5.55e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL8—rheumatoid arthritis	8.48e-07	5.47e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK8—rheumatoid arthritis	8.45e-07	5.45e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CAT—rheumatoid arthritis	8.43e-07	5.44e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—rheumatoid arthritis	8.39e-07	5.42e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—rheumatoid arthritis	8.35e-07	5.39e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—rheumatoid arthritis	8.32e-07	5.37e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—rheumatoid arthritis	8.3e-07	5.36e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—rheumatoid arthritis	8.27e-07	5.34e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—rheumatoid arthritis	8.25e-07	5.32e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—rheumatoid arthritis	8.25e-07	5.32e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—rheumatoid arthritis	8.14e-07	5.25e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—rheumatoid arthritis	8.1e-07	5.23e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MTHFR—rheumatoid arthritis	8.08e-07	5.21e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—rheumatoid arthritis	8.04e-07	5.19e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TYK2—rheumatoid arthritis	7.98e-07	5.15e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CAT—rheumatoid arthritis	7.94e-07	5.13e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—rheumatoid arthritis	7.94e-07	5.12e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CAT—rheumatoid arthritis	7.87e-07	5.08e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOS3—rheumatoid arthritis	7.83e-07	5.05e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—rheumatoid arthritis	7.83e-07	5.05e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—rheumatoid arthritis	7.81e-07	5.04e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NFKB1—rheumatoid arthritis	7.75e-07	5e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—rheumatoid arthritis	7.71e-07	4.97e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—rheumatoid arthritis	7.68e-07	4.96e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—rheumatoid arthritis	7.67e-07	4.95e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—POMC—rheumatoid arthritis	7.63e-07	4.92e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK8—rheumatoid arthritis	7.62e-07	4.91e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NFKB1—rheumatoid arthritis	7.59e-07	4.89e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—rheumatoid arthritis	7.57e-07	4.88e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—rheumatoid arthritis	7.55e-07	4.87e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—rheumatoid arthritis	7.52e-07	4.85e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK8—rheumatoid arthritis	7.46e-07	4.81e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—rheumatoid arthritis	7.4e-07	4.77e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—rheumatoid arthritis	7.37e-07	4.75e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—rheumatoid arthritis	7.33e-07	4.73e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—rheumatoid arthritis	7.27e-07	4.69e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ENO1—rheumatoid arthritis	7.21e-07	4.66e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NFKB1—rheumatoid arthritis	7.19e-07	4.64e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—rheumatoid arthritis	7.16e-07	4.62e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK8—rheumatoid arthritis	7.07e-07	4.56e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—rheumatoid arthritis	7.04e-07	4.54e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—rheumatoid arthritis	7.03e-07	4.54e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—rheumatoid arthritis	6.98e-07	4.5e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—rheumatoid arthritis	6.95e-07	4.49e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—rheumatoid arthritis	6.95e-07	4.48e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—rheumatoid arthritis	6.95e-07	4.48e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—rheumatoid arthritis	6.91e-07	4.46e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—rheumatoid arthritis	6.89e-07	4.44e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—rheumatoid arthritis	6.85e-07	4.42e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—rheumatoid arthritis	6.65e-07	4.29e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—rheumatoid arthritis	6.64e-07	4.28e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—rheumatoid arthritis	6.63e-07	4.28e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—rheumatoid arthritis	6.57e-07	4.24e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—rheumatoid arthritis	6.53e-07	4.21e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—POMC—rheumatoid arthritis	6.46e-07	4.17e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—rheumatoid arthritis	6.45e-07	4.16e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—rheumatoid arthritis	6.33e-07	4.08e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—rheumatoid arthritis	6.32e-07	4.08e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—rheumatoid arthritis	6.28e-07	4.06e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—rheumatoid arthritis	6.27e-07	4.04e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—rheumatoid arthritis	6.23e-07	4.02e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NFKB1—rheumatoid arthritis	6.22e-07	4.01e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK8—rheumatoid arthritis	6.11e-07	3.94e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—rheumatoid arthritis	6.08e-07	3.93e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—rheumatoid arthritis	6.04e-07	3.9e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—rheumatoid arthritis	5.99e-07	3.87e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—rheumatoid arthritis	5.9e-07	3.81e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—rheumatoid arthritis	5.89e-07	3.8e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—rheumatoid arthritis	5.7e-07	3.68e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—rheumatoid arthritis	5.64e-07	3.64e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—rheumatoid arthritis	5.63e-07	3.63e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—POMC—rheumatoid arthritis	5.63e-07	3.63e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—rheumatoid arthritis	5.57e-07	3.6e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—rheumatoid arthritis	5.4e-07	3.48e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—rheumatoid arthritis	5.31e-07	3.43e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—POMC—rheumatoid arthritis	5.3e-07	3.42e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—POMC—rheumatoid arthritis	5.26e-07	3.39e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—rheumatoid arthritis	5.2e-07	3.36e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAT—rheumatoid arthritis	5.19e-07	3.35e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—rheumatoid arthritis	5.18e-07	3.34e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—rheumatoid arthritis	5.15e-07	3.32e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—rheumatoid arthritis	5.13e-07	3.31e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—rheumatoid arthritis	4.93e-07	3.18e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—rheumatoid arthritis	4.91e-07	3.17e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—rheumatoid arthritis	4.86e-07	3.14e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—rheumatoid arthritis	4.83e-07	3.12e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—rheumatoid arthritis	4.79e-07	3.09e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—rheumatoid arthritis	4.76e-07	3.07e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—rheumatoid arthritis	4.62e-07	2.98e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—rheumatoid arthritis	4.58e-07	2.96e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—rheumatoid arthritis	4.51e-07	2.91e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—rheumatoid arthritis	4.49e-07	2.9e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—rheumatoid arthritis	4.33e-07	2.8e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—rheumatoid arthritis	4.26e-07	2.75e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—rheumatoid arthritis	4.23e-07	2.73e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—rheumatoid arthritis	4.19e-07	2.7e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—rheumatoid arthritis	3.9e-07	2.52e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—POMC—rheumatoid arthritis	3.47e-07	2.24e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—rheumatoid arthritis	3.16e-07	2.04e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—rheumatoid arthritis	3.02e-07	1.95e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—rheumatoid arthritis	2.76e-07	1.78e-06	CbGpPWpGaD
